한빛사논문
- 조회482
POSTECH
Jisoo Kim1, Jungmin Kim2, Ge Gao3, Yoo-mi Choi4, Jaewook Kim5, Dong-Woo Cho5,6,* Jae-Ho Cheong2,7,8,9,10,* and Jinah Jang4,5,11*
1School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang, 37673 South Korea
2Department of Surgery, Yonsei University College of Medicine, Seoul, 03722 South Korea
3School of Medical Technology, Beijing Institute of Technology, Beijing, China
4Department of Creative IT Engineering, Pohang University of Science and Technology (POSTECH), Pohang, 37673 South Korea
5Department of Mechanical Engineering, Pohang University of Science and Technology (POSTECH), Pohang, 37673 South Korea
6School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang, 37673 South Korea
7Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, Seoul, 03722 South Korea
8Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722 South Korea
9Chronic Intractable Disease for Systems Medicine Research Center, Yonsei University College of Medicine, Seoul, 03722 South Korea
10Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, 03722 South Korea
11School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang, 37673 South Korea
Jisoo K. and Jungmin K. contributed equally to this work.
Abstract
Accurate prediction of treatment response for cancer patients is essential for overcoming intrinsic therapy resistance that results from genetic heterogeneity, varying tumor growth kinetics, and the complex tumor microenvironment. To achieve this goal, there is an urgent need for effective preclinical in vitro models that recapitulate the molecular–pathologic features and intricate ecology of native tumors for precision medicine. In this study, a vascularized organoid model (VOM) composed of patient-derived gastric cancer organoids (PDOs), perfusable endothelium, and stomach decellularized extracellular matrix is presented that enables the prediction of clinical response to VEGFR2-targeted therapy in gastric cancer patients. The results indicate that VOMs are dependent on the PDO molecular subtype. Moreover, VOMs accurately reproduce the clinically observed responses of patients treated with VEGFR2 inhibitor. Therefore, VOMs represent a valuable platform for providing clinical predictions for personalized testing and potential discovery of therapeutic drugs in various cancers that lack standardized regimens.
논문정보
- Research article
- 2023년 12월 (BRIC 등록일 2024-01-08)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 다학제 융합/복합
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
관련분야 논문보기
